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Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast
cancer patients who received an OncotypeDx recurrence score (RS). Materials and Methods. Pathology records were used to
identify breast cancer patients who had OncotypeDx testing between December 2004 and January 2009 (n = 118). Patient
sociodemographic information, tumor characteristics, RS, and treatment-specific data were collected via chart review. RS was
classified as follows: low (RS ≤ 17), intermediate (RS = 18–30), or high (RS ≥ 31). Bivariate analyses were conducted to
investigate the relationship between adjuvant chemotherapy receipt and each sociodemographic and clinical characteristic;
significant sociodemographic and clinical variables were included in a multivariable logistic regression model. Results. In
multivariable analysis controlling for tumor size, histologic grade, and nuclear grade, only RS remained significantly associated
with chemotherapy uptake. Relative to low RS, an intermediate (adjusted odds ratio [AOR], 21.24; 95% confidence interval
[CI], 3.62–237.52) or high (AOR, 15.07; 95% CI, 1.28–288.21) RS was associated with a greater odds of chemotherapy uptake.
Discussion. Results indicate that RS was significantly associated with adjuvant chemotherapy uptake, suggesting that OncotypeDx
results were used to inform treatment decision making, although it is unclear if and how the information was conveyed to patients.

1. Introduction
An estimated 226,870 new cases of breast cancer are expected
to be diagnosed in 2012 and account for about 29% of all new
cancer cases among US women [1]. Adjuvant chemotherapy
is one treatment option for breast cancer patients that
is used because of its potential to reduce the risk of
breast cancer recurrence and mortality [2]; however, not all
patients benefit from adjuvant chemotherapy [3]. Moreover,
chemotherapy may be detrimental to quality of life given its
potential to produce toxicities, including myelosuppression
[2].

The quality of breast cancer care can be improved by
informing treatment selection based on individual patient
genomic risk profiles [4]; however, to realize the greatest benefits, advances in predictive models that inform treatment
decisions must be accepted and used by healthcare providers
and patients [5]. One example of predictive modeling that
is rapidly moving into the breast oncology care setting
is OncotypeDx testing [4, 6]. Based on the expression of
21 genes obtained from tumor tissue, OncotypeDx testing
calculates the risk of breast cancer distant recurrence (i.e.,
the chance of breast cancer returning as metastatic disease)
in patients with estrogen receptor (ER) positive early breast
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cancer treated with adjuvant endocrine therapy and predicts
the clinical benefit with additional adjuvant chemotherapy.
Given that approximately 75% of breast cancers are ER
positive and 61% of those cases are lymph node (LN)
negative [7], many women with breast cancer may be
qualified and benefit from OncotypeDx testing.
Although there are clinical guidelines to identify patients
who would derive the greatest benefit from OncotypeDx
testing [6], relatively few studies have been conducted to
examine the impact of test results on treatment decisions.
Some research has indicated that OncotypeDx recurrence
score (RS) results have impacted receipt of chemotherapy, including a study of 276 patients who were newly
diagnosed with breast cancer between 2005 and 2009 [8].
After controlling for Nottingham Prognostic Index, adjuvant
online mortality risk, progesterone receptor (PR) status, and
medical oncologists’ blinded recommendation for adjuvant
chemotherapy, only RS and patient age at diagnosis were
significantly associated with receipt of adjuvant chemotherapy. Other studies have linked RS results to changes in
adjuvant chemotherapy plans [8–12]. For instance, one study
conducted from 2004 to 2006 examined the impact of RS on
29 patients with ER positive and LN negative breast cancer
[9]. Results showed that RS changed chemotherapy plans for
9 patients such that 7 of 13 patients for whom chemotherapy
was recommended did not receive it, and 2 of 16 patients
received chemotherapy after initial recommendations against
it.
Though some research has pointed to an association
between RS and receipt of adjuvant chemotherapy, currently
only one published study collected data beyond 2008 [8].
The current study serves to replicate these findings in
another population, with the primary purpose of evaluating
whether OncotypeDx test results predict receipt of adjuvant
chemotherapy in a cohort of consecutive patients with breast
cancer who received an OncotypeDx RS.

2. Materials and Methods
The study population was comprised of patients treated at
Moﬃtt Cancer Center, a large National Cancer Institutedesignated comprehensive cancer center in the southeastern
US. Approximately 60% of all patients seen at Moﬃtt come
from the surrounding seven county catchment area, with the
remainder of patients coming from other Florida counties,
states, and countries. Upon Institutional Review Board
approval, Moﬃtt Cancer Center surgical pathology records
were used to identify patients meeting the following criteria
(1) diagnosed with breast cancer, and (2) had OncotypeDx
testing between December 2004 (the year in which the test
was approved by the U.S. Food and Drug Administration)
and January 2009 (the year in which chart reviews were
completed). Based on this information, medical records were
reviewed retrospectively to collect patient sociodemographic
information, tumor characteristics, OncotypeDx RS, and
treatment-specific data. Chart abstractions were performed
by a study team member after training from the principal
investigator. The senior study coordinator reviewed 10% of
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data files to assess the accuracy of collected data. Finally,
a medical oncologist reviewed the summarized data and
identified a subset (∼10% of charts) for additional review to
ensure accuracy.
2.1. Measures. Sociodemographic data included age; marital,
parental, and menopause status; race/ethnicity; and family
history of breast cancer (present/absent). Clinical characteristics included breast cancer stage; tumor size; LN status; histology; modified combined histologic (Nottingham) grade;
nuclear grade; human epidermal growth factor receptor-2
(HER2), ER, PR, and angiolymphatic invasion status; and
RS. Regarding RS, patients were classified into one of three
groups based on cut points: low (RS ≤ 17), intermediate
(RS = 18–30), or high (RS ≥ 31) [13]. The primary outcome
variable, receipt of adjuvant chemotherapy, was based on
grouping women into those who had chemotherapy versus
those who did not. This comparison was selected as it most
closely reflects the primary treatment decision influenced by
OncotypeDx results [6, 13].
2.2. Data Analyses. Bivariate analyses were used to investigate the relationship between the primary outcome variable,
receipt of adjuvant chemotherapy, and the sample sociodemographic and clinical characteristics. Pearson Chi-square
or Fisher’s Exact tests were used to study relationships with
each categorical variable of interest; a t-test was conducted to
examine diﬀerences in age and RS by chemotherapy uptake
group. Analyses used two-tailed tests of significance with the
significance level set at P < 0.05.
In an eﬀort to maintain an acceptable case-to-variable
ratio, independent variables included in the final multivariable logistic regression model were selected based on
variables significant in the bivariate analyses. Odds ratios
(OR) and their 95% confidence interval (CI) were estimated
from the logistic regression model. Given the variables’ small
expected cell counts, an exact analysis was conducted. Analyses were performed using the SAS 9.1 statistical software
package (SAS Institute Inc, Cary, North Carolina).

3. Results
Chemotherapy status was unknown for 8 patients; data for
the remaining 118 patients were used for analyses. Patient
demographic and clinical characteristics are presented in
Table 1. Patients’ mean age was 56.3 years (SD = 11.0; range:
33–84). Most participants were married or living with a
partner (70.3%), White (84.8%), had children (72.0%), and
were perimenopausal/postmenopausal (63.6%). Just over
half (52.5%) had no family history of breast cancer.
Most patients had stage I breast cancer (80.5%), a tumor
size >1.0 cm (78.8%), and were LN negative (95.8%). The
majority (84.8%) had invasive ductal carcinoma (IDC), and
over half (56.8%) of the tumors showed intermediate histologic grade. The largest proportion of patients had a nuclear
grade of 2 (47.5%). Most patients’ tumors were HER2
negative (94.9%), ER positive (99.2%), PR positive (89.0%),
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Table 1

(a) Patient demographic and clinical characteristics by chemotherapy group (N = 118)a

Chemotherapy
Characteristics
Demographic
Age in years mean (SD)
Marital status
Married/living with partner
Other
Parental status
Children
No children
Menopause status
Premenopause
Perimenopause/postmenopause
Race/ethnicity
White
Other
Family history
Absent
Present
Clinical
Breast cancer stage
I
II A
II B
III/III B
Tumor size (mean in cm)
≤.5 cm
0.6–1.0 cm
>1.0 cm
Lymph node
Positive
Negative
Histology
IDC
ILC
Mixed
Other
Histologic grade
Low
Intermediate
High

Total
(N = 118) n (%)

Yes
(n = 35) n (%)

No
(n = 83) n (%)

Pb

56.3 (11.0)

54.1 (10.4)

57.3 (11.1)

.1513
.0968

83 (70.3)
33 (28.0)

28 (80.0)
6 (17.1)

55 (66.3)
27 (32.5)
.6933

85 (72.0)
28 (23.7)

24 (68.6)
9 (25.7)

61 (73.5)
19 (22.9)

38 (32.2)
75 (63.6)

14 (40.0)
19 (54.3)

24 (28.9)
56 (67.5)

100 (84.8)
17 (14.4)

29 (82.9)
6 (17.1)

71 (85.5)
11 (13.3)

.2037

.6003

.5314
62 (52.5)
55 (46.6)

17 (48.6)
18 (51.4)

45 (54.2)
37 (44.6)

95 (80.5)
19 (16.1)
2 (1.7)
2 (1.7)
1.6
3 (2.5)
22 (18.6)
93 (78.8)

25 (71.4)
8 (22.9)
0 (0.0)
2 (5.7)
1.8
1 (2.9)
2 (5.7)
32 (91.4)

70 (84.3)
11 (13.3)
2 (2.4)
0 (0.0)
1.5
2 (2.4)
20 (24.1)
61 (73.5)

4 (3.4)
113 (95.8)

1 (2.9)
34 (97.1)

3 (3.6)
79 (95.2)

100 (84.8)
7 (5.9)
9 (7.6)
2 (1.7)

33 (94.3)
2 (5.7)
0 (0.0)
0 (0.0)

67 (80.7)
5 (6.0)
9 (10.8)
2 (2.4)

.0595

.0694
.0462∗

1.0000

.1542

.0160∗
33 (28.0)
67 (56.8)
17 (14.4)

7 (20.0)
18 (51.4)
10 (28.6)

26 (31.3)
49 (59.0)
7 (8.4)

(b) Patient demographic and clinical characteristics by chemotherapy group

Chemotherapy
Characteristics
Nuclear grade
1
2
3

Total
(N = 118)

Yes
(n = 35)

No
(n = 83)

Pa
.0004∗

6 (5.1)
56 (47.5)
24 (20.3)

1 (2.9)
8 (22.9)
14 (40.0)

5 (6.0)
48 (57.8)
10 (12.1)
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(b) Continued.

Chemotherapy
Characteristics
HER2
Positive
Negative
ER
Positive
Negative
PR
Positive
Negative
Angiolymphatic invasion
Absent
Present
Recurrence score (mean)
Low
Intermediate
High
a

Total
(N = 118)

Yes
(n = 35)

No
(n = 83)

6 (5.1)
112 (94.9)

3 (8.6)
32 (91.4)

3 (3.6)
80 (96.4)

117 (99.2)
1 (0.9)

34 (97.1)
1 (2.9)

83 (100.0)
0 (0.0)

105 (89.0)
13 (11.0)

28 (80.0)
7 (20.0)

77 (92.8)
6 (7.2)

86 (72.9)
20 (17.0)
19.0
68 (57.6)
37 (31.4)
13 (11.0)

23 (65.7)
9 (25.7)
26.4
4 (11.4)
24 (68.6)
7 (20.0)

63 (75.9)
11 (13.3)
15.9
64 (77.1)
13 (15.7)
6 (7.2)

Pa
.3598

.2966

.0560

.1092

<.0001∗
<.0001∗

Percentages may not total 100 as a result of rounding or missing data, or both.

b A chi-square or Fisher’s exact test was used for categorical variables, and an independent samples t-test was used to compare means for the age, tumor size,

and recurrence risk score variables.

and did not show angiolymphatic invasion (72.9%). The
mean RS was 19.0 and the largest proportion of patients had
a low RS (57.6%).
In bivariate analyses, tumor size, histologic grade, nuclear
grade, and RS were significantly associated with uptake of
adjuvant chemotherapy (Table 1). Compared to patients
who did not receive chemotherapy, those who received
chemotherapy had a greater proportion of tumor size
>1.0 cm (91.4% versus 73.5%), high histologic grade (28.6%
versus 8.4%), nuclear grade of 3 (40.0% versus 12.1%),
intermediate (68.6% versus 15.7%) and high (20.0% versus
7.2%) RS category, and higher mean RS (26.4 versus 15.9). In
multivariable analysis controlling for tumor size, histologic
grade, and nuclear grade, only RS remained statistically
significantly associated with chemotherapy receipt (Table 2).
Relative to those with a low RS, those with an intermediate
(adjusted odds ratio [AOR], 21.24; 95% CI, 3.62–237.52) or
high (AOR, 15.07; 95% CI, 1.28–288.21) RS had a greater
odds of chemotherapy uptake.

Table 2: Logistic regression for uptake of adjuvant chemotherapy
(n = 85).

4. Discussion

∗

Study results indicate that RS was significantly associated
with adjuvant chemotherapy uptake, suggesting that in our
sample of female breast cancer patients who underwent
OncotypeDx testing, the results of this gene assay were
likely being used to inform treatment decision making,
although it is unclear if and how the information was
conveyed to patients. RS score was a significant predictor
of chemotherapy uptake after controlling for more standard clinicopathological markers used to guide treatment

Variable
Adjusted odds ratio (95% confidence interval)
Tumor size
≤.5 cm
Reference
0.6–1.0 cm
0.21 (0.00–32.74)
>1.0 cm
1.24 (0.03–138.62)
Histologic grade
Low
Reference
Intermediate
0.62 (0.05–8.16)
High
0.33 (0.01–9.71)
Nuclear grade
1
Reference
2
0.74 (0.01–122.90)
3
2.42 (0.02–563.30)
Recurrence score∗
Low
Reference
Intermediate
21.24 (3.62–237.52)
High
15.07 (1.28–288.21)
P < .05.

selection, specifically tumor size, LN status, histologic grade,
and nuclear grade. These results are consistent with earlier
research that has shown that RS was associated with whether
patients received adjuvant chemotherapy or not [8–12].
Adjuvant chemotherapy is recommended for individuals
with RS scores in the high-risk category, whereas it is unlikely
to benefit individuals in the low-risk category [13, 14].
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In our study, patients with a low RS were least likely to
receive adjuvant chemotherapy (94% of low-risk patients did
not receive chemotherapy). This finding is consistent with
research showing that RS aﬀects treatment decision-making
for low-risk patients [15] and is similar to the Ademuyiwa
study [8], which reported that 91% of patients with a low RS
did not receive chemotherapy.
Although National Comprehensive Cancer Network
guidelines recommend chemotherapy for individuals with
high RS, in our patient population, only 54% of individuals
with high RS received chemotherapy. This percentage is
lower than that of the Ademuyiwa study [8], which reported
that 96% of patients with high RS received chemotherapy.
For our sample of patients in these higher risk categories,
the receipt of chemotherapy is likely multifactorial (based
on coexisting clinicopathological features). Due to the small
sample sizes in this study, we were unable to more fully
investigate the patterns of treatment choice based on these
multiple factors.
Of interest was the finding that one ER negative patient
and four LN positive patients received an RS, even though
the test has been validated for ER positive and LN negative
breast cancer patients at the time OncotypeDx testing was
performed. The ER negative patient was HER2 negative
and T1cN0. All LN positive patients were HER2 negative
with primary tumor categories ranging from one to four.
Additionally, there were six HER2 positive patients who
received an RS, one of whom was T1aN0, four were T1bN0,
and one was T1cN0. It is possible that the RS was felt to be
of utility for these patients, and perceived as an additional
measure of breast cancer recurrence risk to support a
decision about adjuvant chemotherapy, as was noted in one
patient chart.
Most of the published literature regarding the use of RS
to guide treatment selection focuses on physicians’ use of
this information in guiding treatment selection [8, 10], with
limited evaluation of the patient’s role in the decision to
pursue a therapy. Factors that patients may consider in their
treatment decisions include side eﬀects that can adversely
aﬀect quality of life, patient preference for participation
in treatment decision-making, and understanding of the
results; the latter may be particularly critical where greatest
uncertainty exists, that is, for patients with an intermediate
RS. A preference for an active role in decision-making
among those presented with OncotypeDx results is related
to health literacy, such that women with high-health literacy
prefer a more active role in decision-making, whereas lowhealth literacy is related to preference for more shared and
passive decision-making [16]. Our group recently completed
a retrospective cross-sectional survey of a subset of the
patients (n = 64) included in the present study and found
that women incorrectly answered approximately half of a
series of 14 items evaluating knowledge about RS [17].
Another similarly designed study of 77 breast cancer patients
found that one-third of participants did not fully understand
discussions related to RS [18]. Although not a focus of
this study, it would be of interest to investigate how these
variables interact to guide treatment planning for patients in
the higher-risk RS categories.
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To date, much of the research on OncotypeDx results’
association with treatment decision-making has occurred
in an academic setting. Some research conducted with
an inner-city population suggests that OncotypeDx results
may influence chemotherapy treatment decisions in this
setting [19]. In this sample of 47 women who underwent
OncotypeDx testing, 5% of women with a low RS and
100% of women with a high RS received chemotherapy.
The results for women with a low RS are aligned with
the current study and Ademuyiwa study [8], and results
for women with a high RS are similar to the Ademuyiwa
study. More research needs to be conducted with larger
samples of women from populations outside of the academic
setting.
This study has several limitations. First, the confidence
intervals for the RS categories were wide, thus estimates may
be imprecise. This is likely an eﬀect of the relatively small
sample size. Second, although several clinicopathological and
demographic variables were included in the study, the small
sample sizes limited our ability to further elucidate trends
among individuals in the higher-risk RS categories who did
not receive adjuvant chemotherapy. Third, family history was
recorded in the patient’s chart based on patient self-report
and, like other self-report data, may be inaccurate; however,
some research on the concordance between self-report of
family breast cancer history and cancer confirmation sources
(e.g., state tumor registry) suggests a sensitivity ranging
from 61% to 95% [20, 21]. Fourth, as the study was
retrospective, we were unable to assess definitively whether
treatment planning was changed as a result of the availability
of the RS score and whether patients themselves were able
to use the RS to aid their treatment decision. Also, we
did not account for the possible role that comorbidity
may have played in the uptake of chemotherapy. Given
that higher comorbidity has been linked to a decreased
likelihood of receiving chemotherapy among women aged
55 and older [22], it is possible that comorbid conditions
may also have been associated with chemotherapy among
older women in the current study. Another limitation
is the relatively heterogenous population with regard to
race/ethnicity. Although reflective of the patient population
at this institution, findings may not be generalizable to
other races and ethnicities. Finally, some patients may have
received chemotherapy after the data collection period ended
and this change in chemotherapy receipt status was not
reflected in the analyses.
In summary, the current study oﬀers relatively recent
data to support results of previous research documenting
a change in treatment selection based on the use of
the RS [8–12]. The literature remains in need of studies
investigating the variables associated with a patient’s use
of this valuable health information, including the potential role of comorbidities, as well as studies conducted
with populations outside of the academic setting. This
paper has important implications for prevention, such
that women with a lower risk of breast cancer recurrence
as determined by OncotypeDx testing may be able to
avoid the potential toxicity associated with chemotherapy.
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